DNTH · Dianthus Therapeutics, Inc. /DE/
$115.96
+6.36 (+5.80%)
At close · Aug 14
Market Cap
$6.49B
Shares
55.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$115.96
Open$108.96
Day$108.77–116.47
52W close$20.25–115.96
Avg vol 30d880K
Short int8.4M · 15.0% float · 9.5d
Short vol63%
Last earningsMar 9, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Jan 10, 2027
Est · unconfirmed
· in 21 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+65%
above
Price vs 50-day avg
+19%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
100%
near high
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+120%
trailing
YTD return
+181%
this year
Relative strength
+106%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $97 › 200d $70 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +62 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.98% of float · ▼ -9.1% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
267 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
−67%
Y/Y
EPS growth
−65%
Y/Y
Free cash flow
$-129.4M
Balance sheet
$51.1M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+65%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $97 › 200d $70 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +62 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.98% of float · ▼ -9.1% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
267 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $20
Now $116 · 100%
Range high $116
vs 200-day avg +65%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNTH
this stock
Dianthus Therapeutics, Inc. /DE/
|
$6.49B | +181.4% | -67.3% | — | 15.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNTH | +6.5% | +9.8% | +120.1% | +8.5% | +181.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +6.1% | +5.4% | +106.4% | +4.5% | +167.5% |
Key facts
CIK
1690585
CUSIP
252828108
13F (30d)
263 filings
259 filers
Visit website
Investor relations